Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Silence Therapeutics Plc's Business Segments
Silence Therapeutics Plc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
UK
Total Revenue
-
Regions Reported
-
Revenue Share by Reportable Segment - FY
- UK0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| UK | $ 0 | - |
Annual Results
Revenue Share by Reportable Segment - FY
- UK0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| UK | $ 0 | - |
Description of Silence Therapeutics Plc
Silence Therapeutics Plc is a biotechnology company that specializes in the discovery, development, and delivery of innovative genetic medicines to treat various diseases. The company was founded in 1997 and is headquartered in London, United Kingdom.
Silence Therapeutics focuses on a cutting-edge therapeutic approach called RNA interference (RNAi), which utilizes small interfering RNA (siRNA) molecules to target and silence specific disease-causing genes. The company's proprietary platform technology allows for the design and development of highly specific siRNA molecules, which can effectively silence the expression of target genes.
One of the key advantages of Silence Therapeutics' platform is its ability to deliver siRNA molecules to specific tissues or cells within the body. This targeted delivery system ensures that the therapeutic effect is maximized while minimizing any potential off-target effects. The company has developed multiple delivery methods, including lipid nanoparticles and AtuPLEX, to ensure efficient siRNA uptake and distribution.
Silence Therapeutics has a broad and diverse pipeline of therapeutic candidates targeting various diseases. The company is actively involved in the development of treatments for cardiovascular disease, cancer, genetic disorders, and other inflammatory and metabolic conditions. Some of their most advanced programs include SLN124 for the treatment of iron overload disorders and SLN360 for the treatment of cardiovascular diseases.
In addition to its internal pipeline, Silence Therapeutics also collaborates with other pharmaceutical companies and research institutions to develop novel therapeutic approaches. The company has established partnerships with renowned organizations such as AstraZeneca, Mallinckrodt Pharmaceuticals, and MiNA Therapeutics to leverage its RNAi technology in combination with other drugs or delivery systems.
Silence Therapeutics has a robust intellectual property portfolio, including a number of patents covering its siRNA technology and delivery methods. This provides the company with a competitive advantage and helps ensure its continued ability to innovate and develop breakthrough therapies.
As of 2021, Silence Therapeutics is a publicly traded company listed on the AIM market of the London Stock Exchange. The company has a dedicated team of scientists, researchers, and business professionals, who are committed to advancing the field of RNAi therapeutics and improving patients' lives worldwide.
Overall, Silence Therapeutics Plc is a leading biotechnology company focused on developing innovative genetic medicines using its proprietary RNAi platform. With a strong pipeline, strategic partnerships, and a commitment to scientific excellence, the company is poised to make significant contributions to the field of genetic medicine in the years to come.
Silence Therapeutics focuses on a cutting-edge therapeutic approach called RNA interference (RNAi), which utilizes small interfering RNA (siRNA) molecules to target and silence specific disease-causing genes. The company's proprietary platform technology allows for the design and development of highly specific siRNA molecules, which can effectively silence the expression of target genes.
One of the key advantages of Silence Therapeutics' platform is its ability to deliver siRNA molecules to specific tissues or cells within the body. This targeted delivery system ensures that the therapeutic effect is maximized while minimizing any potential off-target effects. The company has developed multiple delivery methods, including lipid nanoparticles and AtuPLEX, to ensure efficient siRNA uptake and distribution.
Silence Therapeutics has a broad and diverse pipeline of therapeutic candidates targeting various diseases. The company is actively involved in the development of treatments for cardiovascular disease, cancer, genetic disorders, and other inflammatory and metabolic conditions. Some of their most advanced programs include SLN124 for the treatment of iron overload disorders and SLN360 for the treatment of cardiovascular diseases.
In addition to its internal pipeline, Silence Therapeutics also collaborates with other pharmaceutical companies and research institutions to develop novel therapeutic approaches. The company has established partnerships with renowned organizations such as AstraZeneca, Mallinckrodt Pharmaceuticals, and MiNA Therapeutics to leverage its RNAi technology in combination with other drugs or delivery systems.
Silence Therapeutics has a robust intellectual property portfolio, including a number of patents covering its siRNA technology and delivery methods. This provides the company with a competitive advantage and helps ensure its continued ability to innovate and develop breakthrough therapies.
As of 2021, Silence Therapeutics is a publicly traded company listed on the AIM market of the London Stock Exchange. The company has a dedicated team of scientists, researchers, and business professionals, who are committed to advancing the field of RNAi therapeutics and improving patients' lives worldwide.
Overall, Silence Therapeutics Plc is a leading biotechnology company focused on developing innovative genetic medicines using its proprietary RNAi platform. With a strong pipeline, strategic partnerships, and a commitment to scientific excellence, the company is poised to make significant contributions to the field of genetic medicine in the years to come.
Silence Therapeutics Plc is a biotechnology company focused on the development of RNA interference (RNAi) therapeutics. The company specializes in silencing the genes associated with disease, leveraging its proprietary technology platform. Here’s an extensive overview of the segments, products, and services of Silence Therapeutics PLC.
Segments:
1. Research and Development (R&D):
- Cutting-Edge Technology: Silence Therapeutics is at the forefront of RNAi technology. The companys approach involves the use of therapeutic small interfering RNAs (siRNAs) designed to specifically target and degrade mRNAs associated with disease. This precision allows for a tailored therapeutic approach.
- Platform Development: Silence Therapeutics continually invests in refining its RNAi delivery mechanisms, optimizing their technology for increased efficacy, and reduced off-target effects.
2. Clinical Development:
- The company conducts extensive clinical trials to validate the safety and efficacy of its RNAi therapeutics. This segment often includes partnerships with clinical research organizations and academic institutions to support phases I, II, and III trials.
3. Commercial Operations:
- While primarily a research-focused company, Silence Therapeutics may explore collaborations and strategic alliances with larger pharmaceutical companies for commercialization of its products once they reach market readiness.
4. Partnerships and Collaborations:
- Silence Therapeutics actively seeks partnerships for co-development of therapeutics, leveraging external expertise and resources to advance its clinical candidates.
Products:
1. SLN-501:
- An investigational therapeutic designed for the treatment of liver diseases. It targets specific genes linked to the pathology of these conditions, aiming to reduce harmful protein production.
2. SLN-601:
- This product candidate targets pertinent conditions such as solid tumors. It leverages the power of RNAi to halt the expression of tumor-associated genes, potentially offering a novel treatment option for cancer patients.
3. PLK1 Program:
- A program aimed at cancers where the polo-like kinase 1 (PLK1) gene is overexpressed. The developed siRNA candidates intend to selectively inhibit this gene, contributing to tumor growth suppression.
4. Expansion into Cardiovascular and Rare Diseases:
- Silence Therapeutics is also focusing on developing therapies that target genetic disorders affecting the cardiovascular system and other rare diseases. This expansion signals the company’s commitment to tackling a broader range of health conditions.
Services:
1. Custom RNAi Design:
- Silence Therapeutics offers specialized services for the design of custom RNAi molecules tailored to specific gene targets. This service is valuable for pharmaceutical companies and academic researchers who wish to explore RNAi as a therapeutic strategy.
2. Consultation and Strategy Development:
- The company may provide consultation services for organizations looking to leverage RNAi technology in their research. This includes guidance on experimental design, target selection, and potential clinical applications.
3. Collaborative Research and Development:
- Silence Therapeutics engages in collaborative programs with other biotech firms, where they offer their expertise and technology platform to co-develop new therapeutics.
Conclusion
Overall, Silence Therapeutics Plc is cementing its place as a key player in the RNAi therapeutics space through robust R&D, innovative product development, and strategic partnerships aimed at delivering novel treatment solutions for serious diseases. The combination of cutting-edge science with a focus on clinical relevance positions the company to advance the novel applications of RNAi therapeutics effectively.
Segments:
1. Research and Development (R&D):
- Cutting-Edge Technology: Silence Therapeutics is at the forefront of RNAi technology. The companys approach involves the use of therapeutic small interfering RNAs (siRNAs) designed to specifically target and degrade mRNAs associated with disease. This precision allows for a tailored therapeutic approach.
- Platform Development: Silence Therapeutics continually invests in refining its RNAi delivery mechanisms, optimizing their technology for increased efficacy, and reduced off-target effects.
2. Clinical Development:
- The company conducts extensive clinical trials to validate the safety and efficacy of its RNAi therapeutics. This segment often includes partnerships with clinical research organizations and academic institutions to support phases I, II, and III trials.
3. Commercial Operations:
- While primarily a research-focused company, Silence Therapeutics may explore collaborations and strategic alliances with larger pharmaceutical companies for commercialization of its products once they reach market readiness.
4. Partnerships and Collaborations:
- Silence Therapeutics actively seeks partnerships for co-development of therapeutics, leveraging external expertise and resources to advance its clinical candidates.
Products:
1. SLN-501:
- An investigational therapeutic designed for the treatment of liver diseases. It targets specific genes linked to the pathology of these conditions, aiming to reduce harmful protein production.
2. SLN-601:
- This product candidate targets pertinent conditions such as solid tumors. It leverages the power of RNAi to halt the expression of tumor-associated genes, potentially offering a novel treatment option for cancer patients.
3. PLK1 Program:
- A program aimed at cancers where the polo-like kinase 1 (PLK1) gene is overexpressed. The developed siRNA candidates intend to selectively inhibit this gene, contributing to tumor growth suppression.
4. Expansion into Cardiovascular and Rare Diseases:
- Silence Therapeutics is also focusing on developing therapies that target genetic disorders affecting the cardiovascular system and other rare diseases. This expansion signals the company’s commitment to tackling a broader range of health conditions.
Services:
1. Custom RNAi Design:
- Silence Therapeutics offers specialized services for the design of custom RNAi molecules tailored to specific gene targets. This service is valuable for pharmaceutical companies and academic researchers who wish to explore RNAi as a therapeutic strategy.
2. Consultation and Strategy Development:
- The company may provide consultation services for organizations looking to leverage RNAi technology in their research. This includes guidance on experimental design, target selection, and potential clinical applications.
3. Collaborative Research and Development:
- Silence Therapeutics engages in collaborative programs with other biotech firms, where they offer their expertise and technology platform to co-develop new therapeutics.
Conclusion
Overall, Silence Therapeutics Plc is cementing its place as a key player in the RNAi therapeutics space through robust R&D, innovative product development, and strategic partnerships aimed at delivering novel treatment solutions for serious diseases. The combination of cutting-edge science with a focus on clinical relevance positions the company to advance the novel applications of RNAi therapeutics effectively.